LY03017
/ Luye Group
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 20, 2025
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.
New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia
January 28, 2025
Effect of Food and Age on the Pharmacokinetics of LY03017
(clinicaltrials.gov)
- P1 | N=26 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.
New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia
April 29, 2024
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.
New P1 trial • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Schizophrenia
1 to 3
Of
3
Go to page
1